Vtama (tapinarof) / Japan Tobacco, Guanhao Biotech, Organon - LARVOL DELTA

Efficacy and Safety of Benvitimod Compared with Halometasone in Patients with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial. (PubMed, Dermatol Ther (Heidelb)) - P=N/A | "Benvitimod exhibits efficacy comparable to halometasone in managing moderate-to-severe CHE, along with a favorable safety and a low relapse rate."

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Pruritus

Microbiome-Derived Indole-3-Lactic Acid Attenuates Cutibacterium Acnes-Induced Inflammation via the Aryl Hydrocarbon Receptor Pathway. (PubMed, Int J Mol Sci) - "We evaluated indole-3-lactic acid (ILA), indole-3-acrylic acid (IAA), and indole-3-propionic acid (IPA) in comparison to tapinarof, utilizing C. acnes-stimulated human epidermal keratinocytes and a C. acnes-induced acne mouse model...Collectively, these findings establish ILA as a potent postbiotic that mitigates cutaneous inflammation through selective activation of the AHR. Future studies should prioritize the clinical translation of ILA-based topical formulations, with rigorous evaluation of their efficacy and safety in well-designed human trials, to support their development as a non-antibiotic therapeutic alternative for acne management."

Journal • Acne Vulgaris • Dermatology • Inflammation • Oncology • CYP1B1 • IL17A • IL1B • TNFA

Improvement In Sleep And Family Impact For Pediatric Patients Down To 2 Years Of Age With Atopic Dermatitis Treated With Tapinarof Cream 1% Once Daily In Two Pivotal Phase 3 Trials (AAAAI 2026) - P3 | "At Week 8, mean changes in POEM sleep scores with tapinarof versus vehicle were: 2-6 years, –1.9 vs –0.9 (P<0.0001); 7-11 years, –1.5 vs –1.0 (P=0.0029); and 12-17 years, –1.2 vs –0.6 (P<0.0001). Mean changes in DFI sleep Conclusions Tapinarof demonstrated early and consistent improvements in sleep, including family impact, across all age groups in pediatric patients with AD."

Clinical • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab. (PubMed, J Drugs Dermatol) - "We present the case of a 67-year-old male with ACH who failed multiple therapies, including corticosteroids, topical tapinarof, and oral deucravacitinib, before achieving rapid and sustained improvement with bimekizumab, a monoclonal antibody targeting interleukin-17A and IL-17F. As more case reports document favorable outcomes, bimekizumab may emerge as a valuable treatment option for patients with refractory ACH, offering targeted cytokine blockade in a condition with few effective therapies. &nbsp."

Journal • Dermatitis • Dermatology • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Psoriasis • Pustular Psoriasis • IL17A

Effectiveness of Combinational Therapy With Tapinarof and Narrowband Ultraviolet B for Atopic Dermatitis. (PubMed, J Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

In vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique. (PubMed, J Dtsch Dermatol Ges) - "MPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring."

Journal • Preclinical • Dermatology • Dermatopathology • Immunology • Inflammation • Psoriasis

Adoring: A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Organon and Co | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Efficacy and safety of tapinarof in atopic dermatitis: a frequentist and bayesian meta-analysis of randomized controlled trials. (PubMed, Inflammopharmacology) - "Topical Tapinarof (0.5%, 1%) is effective and well-tolerated for mild to moderate atopic dermatitis, but higher adverse event rates require monitoring."

Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dramatic clearance of periorbital lupus miliaris disseminatus faciei with tapinarof 1% cream. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatology • Immunology • Inflammatory Arthritis • Lupus

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) (clinicaltrials.gov) - P2/3 | N=40 | Enrolling by invitation | Sponsor: Wake Forest University Health Sciences | Trial primary completion date: Dec 2025 ➔ Jul 2026

Trial primary completion date • Dermatology • Immunology • Psoriasis

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis (clinicaltrials.gov) - P3 | N=560 | Completed | Sponsor: Teva Pharmaceuticals USA | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis

Emirates Drug Establishment Approves Tapinarof Cream 1%, A New Treatment For Plaque Psoriasis In Adults And Atopic Dermatitis In Adults And Children 2 Years Of Age And Older (MENAFN news) - "The product is backed by extensive clinical trial data highlighting its efficacy and safety for long-term use as demonstrated in 56-week long clinical studies."

Approval • Atopic Dermatitis • Psoriasis

Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients. (PubMed, Front Immunol) - "Peripheral blood mononuclear cells (PBMCs) from patients with PDAC and healthy donors were isolated and treated ex vivo with two AHR agonists (Carbidopa and Tapinarof) and one antagonist (BAY 2416964). Baseline AHR expression critically shapes the immune response to pharmacological modulation in PBMCs from PDAC patients. These findings suggest that AHR profiling may serve as a clinically relevant biomarker for stratifying patients and guiding personalized immunotherapy approaches for PDAC."

IO biomarker • Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • AHR • IL10 • PD-1 • PD-L1

Adoring: A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis (clinicaltrials.gov) - P3 | N=180 | Not yet recruiting | Sponsor: Organon and Co

New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Pharmacovigilance of Tapinarof Adverse Effects Utilizing the FAERS Database (ISDS 2025) - "Early data suggests most side effects of Tapinarof are related to application site folliculitis and headache, consistent with the side effect profile of Tapinarof. Pharmacovigilance can provide helpful information to either confirm established side effects or potentially provide insight on previously unstudied effects. With increasing use, pharmacovigilance via the FAERS database can provide increased insights into Tapinarof reactions, both rare and common."

Adverse events • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • Psoriasis

The AhR agonist tapinarof suppresses human skin inflammation by inducingmetabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs (ISDS 2025) - "Tapinarof-induced AhR signaling reduced HIF1α and mTOR expression in T cells, limiting glucose uptake, glycolytic capacity, and FA metabolism, while also impairing mitochondrial respiration and ATP production, producing marked metabolic dysfunction. In summary, tapinarof acts at the level of the mitochondria to reduce DAMP sensing via reduced ROS production and mtDNA release, thus markedly reducing inflammatory tone, and by blocking multiple metabolic pathways, thus blocking the cells' ability to use and generate energy in the hypoxic skin microenvironment."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Metabolic Disorders • Psoriasis • HIF1A • mTOR • STING

A Case of Palmoplantar Psoriasis Successfully Treated With Tapinarof Cream. (PubMed, J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

CDSCO Panel Asks Pure and Cure Healthcare To Revise Phase III Protocol of Tapinarof Cream 1% for Adult Psoriasis (Medical Dialogues) - "During the SEC meeting held on 08 October 2025, the expert panel reviewed the submission in detail. Following deliberation, the committee made the following observations:1) Not to include very severe patients of plaque psoriasis and to revise the inclusion criteria accordingly; 2) A washout period should be defined for severe patients who are already on treatment with other drugs, and ethical considerations of the same should be justified; 3) The firm has not mentioned any concomitant medication (like moisturizer); 4) The age of the patients should be revised to 18-60 years; 5) Quantity of application should be defined by fingertip unit (FTU)....Accordingly, the expert panel suggested that the firm should submit the revised protocol for further review by the committee."

New P3 trial • Psoriasis

A systems biology approach to identify key targets in KRAS/BRAF-mutated colorectal cancer. (PubMed, Discov Oncol) - "This study sheds light on the molecular mechanisms of KRAS-mutated CRC, emphasizing IL1B as a prognostic marker. Among the identified therapeutic agents, Omeprazole demonstrated the strongest interaction with AHR, suggesting a potential for repurposing in CRC treatment, while IL1B-targeting inhibitors such as Canakinumab emerged as selective candidates for modulating tumor-promoting inflammation. Novel genes such as EPSTI1, COL20A1, CDH1, and SOX9 warrant further investigation."

Journal • Colorectal Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor • BRAF • CDH1 • EGF • EPSTI1 • IL1B • KRAS • SOX9

Tapinarof Cream 1%, Shows Early and Durable Response in Children With Atopic Dermatitis (Patient Care) - "A new sub-analysis of pooled data from the phase 3 ADORING 1 and 2 trials found that tapinarof (VTAMA) cream, 1%, provided early and consistent efficacy for children aged 2 to 17 with moderate-to-severe atopic dermatitis (AD)....The findings, presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, analyzed 654 children randomized to tapinarof cream 1% or vehicle once daily for 8 weeks. Early improvements in skin clearance were observed...Among children with atopic comorbidities, 42.3% of those treated with tapinarof cream achieved vIGA-AD response compared with 11.8% receiving vehicle (P < 0.0001). In those without comorbidities, response rates were 49.5% with tapinarof vs 14.8% with vehicle (P < 0.0001)."

Retrospective data • Atopic Dermatitis

Impact of Dietary Modifications on Severe Treatment-Resistant Atopic Dermatitis (ACAAI 2025) - "Her disease was refractory to topical and systemic steroids, topical tacrolimus, dupilumab, upadacitinib, and UVB phototherapy...She initially responded to cyclosporine but quickly recrudesced. Tapinarof provided modest improvement but required more dosing than dispensations permitted...Discussion Guidelines recommend against elimination diets in AD given risk of food allergy development. The potential benefits of low-carbohydrate, preservative-free and plastic-free diets warrant further investigation."

Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Eosinophilia • Food Hypersensitivity • Immunology • CARD11 • IL13 • IL5

Product Theater 4 (non-CME) - Organon : Unlock the Potential of VTAMA (ACAAI 2025) - "Sponsored by Organon Description"

Tapinarof Cream 1% Once Daily In Children With Atopic Dermatitis With Or Without Atopic Comorbidities (ACAAI 2025) - "Tapinarof was well tolerated, regardless of atopic comorbidities history. Conclusion Tapinarof demonstrated consistent, clinically meaningful efficacy, improvement in PROs, and was well tolerated in children aged 2-17 years, regardless of atopic comorbidities."

Clinical • Late-breaking abstract • Allergic Rhinitis • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Respiratory Diseases

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects (clinicaltrials.gov) - P3 | N=58 | Active, not recruiting | Sponsor: Organon and Co | Recruiting ➔ Active, not recruiting | N=100 ➔ 58

Enrollment change • Enrollment closed • Dermatology • Immunology • Pediatrics • Psoriasis